Growing at a steady pace, this Healthcare Nanotechnology (Nanomedicine) market research values the industry size in USD million terms for 2020 and expected USD million value by the end of 2025 is provided for decision makers and stakeholders interested in Healthcare Nanotechnology (Nanomedicine) market. The report on Healthcare Nanotechnology (Nanomedicine) market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, etc.

The Healthcare Nanotechnology (Nanomedicine) market research report provides a thorough analysis regarding the production and the consumption patterns of this industry vertical. Based on production aspect, the study offers crucial insights pertaining to the manufacturing patterns of the items, revenue share, and its respective impact on the overall gross margins of the producers.

As per consumption patterns, the document assesses the consumption value and volume regarding each of the product offerings, their sale prices and import & export conditions across various regions listed. Additionally, the report also delivers production and consumption expectations, during the ongoing COVID-19 pandemic.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/140120

Emphasizing on the regional landscape:

Summarizing the product landscape:

Elaborating on the application space:

Highlighting the competitive dynamics:

Briefly, the Healthcare Nanotechnology (Nanomedicine) market research report comprises of a granular assessment regarding the upstream raw materials, downstream buyers, manufacturing equipment and distribution channels. Furthermore, it evaluates the various market dynamics such as opportunities, trends, drivers and limitations & challenges which are impacting the revenue generation of the overall market.

Key Questions Answered in Global Healthcare Nanotechnology (Nanomedicine) market Report: -

The Report Provides The Following Information:

Categorize data at the regional level as well as revenue and growth of in these regions

Distribution channels, and consumption patterns, of the global Healthcare Nanotechnology (Nanomedicine) market

Study data of the market on the basis of the country, including market share and revenue of the important countries

Critical analysis of every market player, such as collaborations, acquisitions, and product launches

Market opportunities, challenges, and threats faced by the vendors in the global Healthcare Nanotechnology (Nanomedicine) market are highlighted

Upstream raw materials and manufacturing equipment are investigated.

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/140120

View original post here:
Global Healthcare Nanotechnology (Nanomedicine) Market Analysis, Size, Share, Growth, Trends and Forecast to 2025 - Express Journal

July 10, 2020 |Animal models are showing how prior infection of the SARS-CoV-2 virus can provide protection against reinfection. Elsewhere, a coronavirus task force task force is examining genes associated with COVID-19 immune response by collecting samples from Japanese patients. This, plus more, are featured in this weeks COVID-19 news from the biotech and research industries.

Literature Updates

Using an animal model for COVID-19, scientists at the University of Wisconsin-Madison, the University of Tokyoand the Icahn School of Medicine at Mount Sinaishow that prior infection with the SARS-CoV-2 virus provides protection against reinfection, and treatment with convalescent serum limits virus replication in their lungs. The study, published in the Proceedings of the National Academy of Sciences, point to the usefulness of Syrian hamsters in trying to understand SARS-CoV-2and in evaluating vaccines, treatments and drugs against the disease it causes. Expanding on earlier work with the animals, researchers demonstrated that both low and high doses of the virus, from patient samples collected in the U.S. and Japan, replicate well in the airways of juvenile and adult hamsters and that the virus can infect both the upper and lower respiratory tracts. The research team also showed that SARS-CoV-2 causes severe disease in the lungs of infected animals, including lesions and the kind of "ground glass" appearance often found in lung scans in human patients. Scans additionally revealed a region of gas in the cavity surrounding the hamster's lungs, indicating severe lung damage. The most severe effects were observed within eight days after infection, and improvement by 10 days. DOI: 10.1073/pnas.2009799117

Researchers at the University of Torontoand National Jewish Health(Denver) have made a drug discovery that shows promise in fighting acute respiratory illnesses such as COVID-19. Called TAT CARMIL1, the "drug" is a combination of two naturally occurring peptides that together penetrate a cell's membrane to douse cytokine storms if deployed early enough. In its first ex vivo study, published in Cell Reports, the peptide duo reduced collagen degradation by up to 43%. It effectively blocks a family of cytokines, called interleukin1, from signaling and reproducing in vast quantities. It precisely targets two receptors, sticking to both the cell's surface and its cell substrate, where it adheres to other cells. Researchers believe the unusual nature of this pathway might restrict its side effects, making TAT CARMIL1 an unusually strong candidate as a potential drug. DOI: 10.1016/j.celrep.2020.107781

An international team of scientists has shown that the G614 variant of the SARS-CoV-2 virus came to dominate cases of COBID-19 around the world by mid-March. Its spike protein differs slightly from the D614 variant, helping the virus copy itself rather than making the virus more deadly(as was initially reported). The study, published in Cell, was led by scientists at Duke University, Los Alamos National Laboratoryand La Jolla Institute(headquarters for the Coronavirus Immunotherapy Consortium). Based on experiments with samples from six San Diego residents, researchers showed that the human immune response could neutralize the new G virus as well or better than the original D virusa finding in line with what doctors saw in COVID-19 patients. DOI: 10.1016/j.cell.2020.06.043

Scientists from theUniversity of South Florida Health(USF Health) Morsani College of Medicine and theUniversity of ArizonaCollege of Pharmacy report in Cell Researchthat theyve identified several existing compounds that block replication of the COVID-19 virus within human cells grown in the laboratory. The inhibitors all demonstrated potent chemical and structural interactions with the SARS-CoV-2 main protease that is critical to the virus's ability to proliferate and has already been validated as an antiviral drug target for genetically similar SARS and MERS. The most promising drug candidates include the FDA-approved hepatitis C medication boceprevirand an investigational veterinary antiviral drug known as GC-376. Calpain inhibitors II and XII, cysteine inhibitors investigated in the past for cancer, neurodegenerative diseases and other conditions, also showed strong antiviral activity. DOI: 10.1038/s41422-020-0356-z

Two recent papers (in Langmuirand ACS Nano) describe a membrane on a chipthat allows continuous monitoring of how drugs and infectious agents interact with human cells. With funding from the U.S. Defense Research Projects Agency, the device will now be used to test potential drug candidates for COVID-19 using virus membranes identical to the SARS-CoV-2 membrane, but which don't contain the viral nucleic acid. The device was developed by researchers from the University of Cambridge, Cornell University andStanford Universityand can mimic any cell type. Their research recently pivoted to how COVID-19 attacks human cell membranes and how it can be blocked. The device, which uses an electronic chip to measure any changes in an overlying membrane extracted from a cell, has been successfully used to monitor the activity of ion channelsthe target of more than 60% of approved pharmaceuticals. It can be as small as the size of a human cell and easily fabricated in arrays. The method is compatible with high-throughput screening and would reduce the number of false positives making it through into the R&D pipeline. DOI: 10.1021/acs.langmuir.0c00804

A researcher at St. Petersburg State University(Russia) has advanced a hypothesis that the severe course of COVID-19 may be associated with von Willebrand factor(VWF), one of the main components of the blood coagulation system. As she explains it, replication of the virus stimulates the development of microdamage on vessel walls that prompts the body to release VWF into the blood to patch possible holes. This increases the risk of thromboses, which has been associated with a significant number of deaths from COVID-19. Different levels of VWF in the blood of patients may explain why infection can happen in completely different ways person to person. VWF levels also differ markedly among healthy peoplee.g., higher among African Americans than Europeans, in men than in women, in adults than in children, and in the elderly than in middle-aged peopleand also appear to be higher among those in blood group A and lower among those in blood group O. The article published in Ecological Genetics. DOI: 10.17816/ecogen33973

Researchers from the University of Houstonand Medistar Corporationreport in Materials Today Physicsthat they have designed a "catch and kill" nickel foam air filter that can trap the virusresponsible for COVID-19, killing it instantly. In testing at the Galveston National Laboratory, run by theUniversity of TexasMedical Branch, they found 99.8% of SARS-CoV-2 was killed in a single pass through the filter when heated to 392 degrees Fahrenheit. It is reportedly compatible with conventional heating, ventilation and air conditioning systems. High-priority venuesincluding hospitals and healthcare facilitieswould be in the initial roll-out of the device. DOI: 10.1016/j.mtphys.2020.100249

Scientists from Germany and Israel have isolated potent SARS-CoV-2 neutralizing antibodieswhich are currently being further characterized and developed together with Boehringer Ingelheim. Theyre expected to enter clinical development later this year. Results, published in Cell,were based on an investigation of the SARS-CoV-2 antibody response in 12 individuals recovered from COVID-19. Of the 255 antibodies reconstructed in the laboratory, 28 neutralizing antibodies were found. SARS-CoV-2-specific B cells carry similar antibody characteristics to those of SARS-CoV-2 neutralizing antibodies, they say, suggesting they can be readily formed and that an active vaccine may provide rapid protection. The antibodies have been developed for protecting against and treating COVID-19 and could also be used for post-exposure prophylaxis. DOI: 10.1016/j.cell.2020.06.044

A researcher at Virginia Tech and two colleagues at the National Institutes of Healthhave found that Bacille Calmette-Gurin (BCG)a tuberculosis vaccineroutinely given to children in countries with high rates of TB infectionmight play a significant role in mitigating mortality rates from COVID-19. Countries with higher rates of BCG vaccinations also had lower peak mortality rates from COVID-19, and the correlation held even after adjusting for variables such as income, access to education and health services, population size and densities, and age distribution. One sample that stood out was Germany, which had different vaccine plans prior to the country's unification in 1990 that has left older Germans (the population most at risk from COVID-19) in the country's eastern states better protected from the current pandemic than their peers in western German states where mortality rates are 2.9 times higher. The BCG vaccines have already been shown to provide broad cross-protections for several viral respiratory illnesses in addition to TB. Researchers stress that the findings are preliminary. The World Health Organization doesnt currently recommend BCG vaccinations for the prevention of COVID-19, but clinical trials are underway to establish whether it confers protection. Their work has published in the Proceedings of the National Academy of Sciences. Article

Using data covering a longer period than previously reported, researchers report in The Journals of Gerontologythat ApoE e4e4 genotype is associated with COVID-19 test positivityat genome-wide significance in the UK Biobank. Similarly, the e4e4 genotype was associated with a four-fold increase in mortality after testing positive for COVID-19. The findings demonstrate that risks for COVID-19 mortality are not simply related to advanced chronological age or the comorbidities commonly seen in aging. DOI: 10.1093/gerona/glaa169

Updates from Industry

A joint research Coronavirus Task Forcehas been established by researchers from eight leading universities and medical institutions in Japan. The task force will examine genes associated with COVID-19 immune response by collecting samples from Japanese patients and apply the findings to development of a mucosal vaccine and predictive modeling for COVID-19 treatment. Its focus is on the fact that the number of COVID-19 deaths per capita among Japanese people is far fewer than those in Western countries. By comparing severe and mild/asymptomatic cases among Japanese people, the group will search for genetic susceptibilities unique to Japanese people associated with exacerbation of COVID-19. As of June 15, collection of patient samples had already begun at 30 facilities, with 60 more awaiting approval from a research ethics committee to start their own large-scale sample collection. The research team plans to collect 600 blood samples from its joint research institutes and use them to conduct comprehensive analyses. After identifying the genes involved in disease exacerbation in Japanese patients, they will try to identify candidate antigens for SARS-CoV-2 using supercomputer simulations. Vaccine efforts will use proprietary molecular needle technology. The goal is to analyze the human genes of samples collected in July and compile results by September. Press release.

The Innovation Center of NanoMedicine(iCONM) has initiated a collaborative study with the Tokyo Metropolitan Institute of Medical Science (TMIMS), aiming to rapidly develop an mRNA vaccinein preparation for the re-pandemic of COVID-19 and attacks by other new coronaviruses. The study will adapt iCONM's basic technologyan mRNA-loaded smart nanomachinesto the TMIMS's expertise in recombinant vaccine discovery. Press release.

The rest is here:
Study Says Prior Infection Could Prevent Reinfection, Other COVID-19 News - Bio-IT World

UPDATE AVAILABLE ON-DEMAND

Nanomedicine is an application of nanotechnology that deals in the prevention & treatment of diseases in humans. This technology uses submicrometer-sized particles for diagnosis, treatment, and prevention of diseases. Nanomedicines are advantageous over generic drugs in several aspects such as, to reduce renal excretion, improve the ability of drugs to accumulate at pathological sites, and enhance the therapeutic index of drugs. Thus, nanomedicine is used in a wide range of applications that include aerospace materials, cosmetics, and medicine.

The global nanomedicine market was valued at $111,912 million in 2016, and is projected to reach $261,063 million by 2023, growing at a CAGR of 12.6% from 2017 to 2023. The drug delivery segment accounted for nearly two-fifths share of the global market in 2016.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/2021

The global market is driven by increase in the development of nanotechnology-based drugs, advantages of nanomedicine in various healthcare applications, and growth in need of therapies with fewer side effects. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, growth of healthcare facilities in emerging economies is anticipated to provide numerous opportunities for the market growth.

The vaccines segment is expected to register a significant CAGR of 13.2% throughout the forecast period. The treatment segment accounted for about fourth-sevenths share in the global market in 2016, accounting for the highest share during the forecast period. This is due to the high demand for therapeutics among patient and rise in the incidence of chronic diseases.

The neurological diseases segment is expected to grow at the highest CAGR of 13.9% during the forecast period, owing to high demand for brain monitoring & treatment devices and drugs. The oncological diseases segment accounted for the highest revenue in 2016, with one-third share of the global market, and is expected to maintain its dominance throughout the forecast period.

In 2016, Asia-Pacific and LAMEA collectively accounted for about one-fourth share of the global market, and is expected to continue this trend due to increased adoption of nanomedicines, especially in China, India, and the other developing economies. In addition, rise in investments by key players in the field of nanomedicines is key driving factor of the Asia-Pacific market.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2021

The Major Key Players Are:

The Other Prominent Players Are:

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

Contact:

David CorreaPortland, OR, United StatesUSA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1(855)550-5975[emailprotected]Web:https://www.alliedmarketresearch.comFollow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

Read this article:
Nanomedicine Market Is New Business Opportunities and Investment Research Report by 2026 - 3rd Watch News

TAU researcher Prof. Dan Peer, from the school of Molecular Cell Biology and Biotechnology, is one of 11 partners in the international project EXPERT that has been awarded a total of 14.9 million EUR from the EU Horizon 2020. The project is working to find efficient ways to deliver protein coding mRNA by using various nanoparticles for the treatment of breast cancer and myocardial infarction, which are two of the most pressing health challenges in European society today.

Prof. Dan Peer, Director, Laboratory of Precision NanoMedicine, School of Molecular Cell Biology and Biotechnology, George S. Wise Faculty of Life Sciences and Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University Center for Nanoscience and Nanotechnology and Tel Aviv University Cancer Biology Research Center.

It is about developing mRNA therapy for the treatment of breast cancer. Much of it involves testing different methods to improve the delivery of mRNA to cells in vivo. These methods are fundamentally based either on lipid nanoparticles (LNPs), biological nanoparticles called exosomes, or cell penetrating peptides (CPPs). In addition to this, we intend to analyze what these nanoparticles bind to in biological fluids in order to better understand what drives uptake in specific cells types.

Our lab was the first to show systemic, cell specific delivery of mRNA molecules that express therapeutic proteins in designated cells. We will further develop our ASSET platform for cell specific targeting of lipid nanoparticles to achieve improved delivery of therapeutic mRNAs and optimize formulations that enable systemic administration in different preclinical models. Part of the work will also consist of understanding how nanoparticle surfaces bind to host factors in blood and how this can affect the uptake of nanoparticles.

We will now see how these delivery methods work side by side in cell culture and animal models. The hope is then to be able to deliver an mRNA cocktail with one of the aforementioned vectors for the treatment of triple-negative breast cancer. In parallel, these vectors will also be evaluated for delivery of VEGF mRNA in the treatment of myocardial infarction.

See the rest here:
New nanomedicines for mRNA therapeutics in breast cancer and heart failure - Mirage News

Global Nanomedicine Market research report delivers comprehensive analysis of the market structure along with estimations of the various segments and sub-segments of the market. This study also analyzes the market status, market share, growth rate, sales volume, future trends, market drivers, market restraints, revenue generation, opportunities and challenges, risks and entry barriers, sales channels, and distributors. The company profiles of all the chief and dominating market players and brands who are taking steps such as product launches, joint ventures, mergers and acquisitions are mentioned in the report. With the use of SWOT analysis and Porters Five Forces analysis which are two of the standard, prominent and full-proof methods, this Global Nanomedicine Market report is been framed.

To prosper in this competitive market place, businesses consider taking up innovative solutions and market research report is one of them. Analysis and estimations derived through the enormous information gathered in this Global Nanomedicine market analysis report are extremely necessary when it comes to dominating the market or creating a mark in the market as a new emergent. A lot of efforts have been put together and no stone is left unturned while generating this report. This Global Nanomedicine market report represents a professional and all-inclusive study of the industry which focuses on primary and secondary drivers, market share, competitor analysis, leading segments and geographical analysis.

Global nanomedicine marketis registering a healthy CAGR of 15.50% in the forecast period of 2019-2026. This rise in the market value can be attributed to increasing number of applications and wide acceptance of the product globally. There is a significant rise in the number of researches done in this field which accelerate growth of nanomedicine market globally.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanomedicine-market

Key Market Competitors

Few of the major market competitors currently working in the global nanomedicine market are Abbott, Invitae Corporation, General Electric Company, Leadiant Biosciences, Inc., Johnson & Johnson Services, Inc., Mallinckrodt, Merck Sharp & Dohme Corp., NanoSphere Health Sciences, Inc., Pfizer Inc., CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Amgen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Luminex Corporation, Eli Lilly and Company, Nanobiotix, Sanofi, UCB S.A., Ablynx among others.

Competitive Landscape

Global nanomedicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of nanomedicine market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Insights in the report:

Complete and distinct analysis of the market drivers and restraints

Key Market players involved in this industry

Detailed analysis of the Market Segmentation

Competitive analysis of the key players involved

Market Drivers are Restraints

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/request-a-discount/global-nanomedicine-market

To comprehend Global Nanomedicine market dynamics in the world mainly, the worldwide Nanomedicine market is analyzed across major global regions.

Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-nanomedicine-market

Nanomedicine Market report effectively provides required features of the global market for the population and for the business looking people for mergers & acquisitions, making investments, new vendors or concerned in searching for the appreciated global market research facilities. It offers sample on the size, offer, and development rate of the market. The Nanomedicine report provides the complete structure and fundamental overview of the industry market.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read the original here:
Global Nanomedicine Market Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Industry Updates, Future Growth, Business Prospects, In-depth...

LOS ANGELES, United States: QY Research has recently published a report, titled Global Oral Contrast Agent Market Insights and Forecast to 2026. The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Oral Contrast Agent market. It informs readers about key trends and opportunities in the global Oral Contrast Agent market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Oral Contrast Agent market.

Key companies operating in the global Oral Contrast Agent market include GE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany), Guerbet (France), Lantheus (US), Daiichi Sankyo (Japan), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals (India), Spago Nanomedicine (Sweden), Taejoon Pharm (South Korea), Jodas (India), Magnus Health (India) Oral Contrast Agent

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1885992/global-oral-contrast-agent-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Oral Contrast Agent market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Oral Contrast Agent Market Segment By Type:

,Barium-based Contrast Media,Iodinated Contrast Media,Gadolinium-based Contrast Media,Microbubble Contrast Media Oral Contrast Agent

Global Oral Contrast Agent Market Segment By Application:

, Cardiovascular Disorders, Cancer, Gastrointestinal Disorders, Musculoskeletal Disorders, Neurological Disorders, Nephrological Disorders

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Oral Contrast Agent market.

Key companies operating in the global Oral Contrast Agent market include GE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany), Guerbet (France), Lantheus (US), Daiichi Sankyo (Japan), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals (India), Spago Nanomedicine (Sweden), Taejoon Pharm (South Korea), Jodas (India), Magnus Health (India) Oral Contrast Agent

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1885992/global-oral-contrast-agent-market

TOC

1 Study Coverage1.1 Oral Contrast Agent Product Introduction1.2 Market Segments1.3 Key Oral Contrast Agent Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Oral Contrast Agent Market Size Growth Rate by Type1.4.2 Barium-based Contrast Media1.4.3 Iodinated Contrast Media1.4.4 Gadolinium-based Contrast Media1.4.5 Microbubble Contrast Media1.5 Market by Application1.5.1 Global Oral Contrast Agent Market Size Growth Rate by Application1.5.2 Cardiovascular Disorders1.5.3 Cancer1.5.4 Gastrointestinal Disorders1.5.5 Musculoskeletal Disorders1.5.6 Neurological Disorders1.5.7 Nephrological Disorders1.6 Study Objectives1.7 Years Considered 2 Executive Summary2.1 Global Oral Contrast Agent Market Size, Estimates and Forecasts2.1.1 Global Oral Contrast Agent Revenue 2015-20262.1.2 Global Oral Contrast Agent Sales 2015-20262.2 Global Oral Contrast Agent, Market Size by Producing Regions: 2015 VS 2020 VS 20262.2.1 Global Oral Contrast Agent Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Oral Contrast Agent Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Oral Contrast Agent Competitor Landscape by Players3.1 Oral Contrast Agent Sales by Manufacturers3.1.1 Oral Contrast Agent Sales by Manufacturers (2015-2020)3.1.2 Oral Contrast Agent Sales Market Share by Manufacturers (2015-2020)3.2 Oral Contrast Agent Revenue by Manufacturers3.2.1 Oral Contrast Agent Revenue by Manufacturers (2015-2020)3.2.2 Oral Contrast Agent Revenue Share by Manufacturers (2015-2020)3.2.3 Global Oral Contrast Agent Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Oral Contrast Agent Revenue in 20193.2.5 Global Oral Contrast Agent Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Oral Contrast Agent Price by Manufacturers3.4 Oral Contrast Agent Manufacturing Base Distribution, Product Types3.4.1 Oral Contrast Agent Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Oral Contrast Agent Product Type3.4.3 Date of International Manufacturers Enter into Oral Contrast Agent Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026)4.1 Global Oral Contrast Agent Market Size by Type (2015-2020)4.1.1 Global Oral Contrast Agent Sales by Type (2015-2020)4.1.2 Global Oral Contrast Agent Revenue by Type (2015-2020)4.1.3 Oral Contrast Agent Average Selling Price (ASP) by Type (2015-2026)4.2 Global Oral Contrast Agent Market Size Forecast by Type (2021-2026)4.2.1 Global Oral Contrast Agent Sales Forecast by Type (2021-2026)4.2.2 Global Oral Contrast Agent Revenue Forecast by Type (2021-2026)4.2.3 Oral Contrast Agent Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Oral Contrast Agent Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Market Size by Application (2015-2026)5.1 Global Oral Contrast Agent Market Size by Application (2015-2020)5.1.1 Global Oral Contrast Agent Sales by Application (2015-2020)5.1.2 Global Oral Contrast Agent Revenue by Application (2015-2020)5.1.3 Oral Contrast Agent Price by Application (2015-2020)5.2 Oral Contrast Agent Market Size Forecast by Application (2021-2026)5.2.1 Global Oral Contrast Agent Sales Forecast by Application (2021-2026)5.2.2 Global Oral Contrast Agent Revenue Forecast by Application (2021-2026)5.2.3 Global Oral Contrast Agent Price Forecast by Application (2021-2026) 6 North America6.1 North America Oral Contrast Agent by Country6.1.1 North America Oral Contrast Agent Sales by Country6.1.2 North America Oral Contrast Agent Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America Oral Contrast Agent Market Facts & Figures by Type6.3 North America Oral Contrast Agent Market Facts & Figures by Application 7 Europe7.1 Europe Oral Contrast Agent by Country7.1.1 Europe Oral Contrast Agent Sales by Country7.1.2 Europe Oral Contrast Agent Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe Oral Contrast Agent Market Facts & Figures by Type7.3 Europe Oral Contrast Agent Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific Oral Contrast Agent by Region8.1.1 Asia Pacific Oral Contrast Agent Sales by Region8.1.2 Asia Pacific Oral Contrast Agent Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific Oral Contrast Agent Market Facts & Figures by Type8.3 Asia Pacific Oral Contrast Agent Market Facts & Figures by Application 9 Latin America9.1 Latin America Oral Contrast Agent by Country9.1.1 Latin America Oral Contrast Agent Sales by Country9.1.2 Latin America Oral Contrast Agent Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America Oral Contrast Agent Market Facts & Figures by Type9.3 Central & South America Oral Contrast Agent Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa Oral Contrast Agent by Country10.1.1 Middle East and Africa Oral Contrast Agent Sales by Country10.1.2 Middle East and Africa Oral Contrast Agent Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 U.A.E10.2 Middle East and Africa Oral Contrast Agent Market Facts & Figures by Type10.3 Middle East and Africa Oral Contrast Agent Market Facts & Figures by Application 11 Company Profiles11.1 GE Healthcare (US)11.1.1 GE Healthcare (US) Corporation Information11.1.2 GE Healthcare (US) Description and Business Overview11.1.3 GE Healthcare (US) Sales, Revenue and Gross Margin (2015-2020)11.1.4 GE Healthcare (US) Oral Contrast Agent Products Offered11.1.5 GE Healthcare (US) Related Developments11.2 Bracco Imaging (Italy)11.2.1 Bracco Imaging (Italy) Corporation Information11.2.2 Bracco Imaging (Italy) Description and Business Overview11.2.3 Bracco Imaging (Italy) Sales, Revenue and Gross Margin (2015-2020)11.2.4 Bracco Imaging (Italy) Oral Contrast Agent Products Offered11.2.5 Bracco Imaging (Italy) Related Developments11.3 Bayer HealthCare (Germany)11.3.1 Bayer HealthCare (Germany) Corporation Information11.3.2 Bayer HealthCare (Germany) Description and Business Overview11.3.3 Bayer HealthCare (Germany) Sales, Revenue and Gross Margin (2015-2020)11.3.4 Bayer HealthCare (Germany) Oral Contrast Agent Products Offered11.3.5 Bayer HealthCare (Germany) Related Developments11.4 Guerbet (France)11.4.1 Guerbet (France) Corporation Information11.4.2 Guerbet (France) Description and Business Overview11.4.3 Guerbet (France) Sales, Revenue and Gross Margin (2015-2020)11.4.4 Guerbet (France) Oral Contrast Agent Products Offered11.4.5 Guerbet (France) Related Developments11.5 Lantheus (US)11.5.1 Lantheus (US) Corporation Information11.5.2 Lantheus (US) Description and Business Overview11.5.3 Lantheus (US) Sales, Revenue and Gross Margin (2015-2020)11.5.4 Lantheus (US) Oral Contrast Agent Products Offered11.5.5 Lantheus (US) Related Developments11.6 Daiichi Sankyo (Japan)11.6.1 Daiichi Sankyo (Japan) Corporation Information11.6.2 Daiichi Sankyo (Japan) Description and Business Overview11.6.3 Daiichi Sankyo (Japan) Sales, Revenue and Gross Margin (2015-2020)11.6.4 Daiichi Sankyo (Japan) Oral Contrast Agent Products Offered11.6.5 Daiichi Sankyo (Japan) Related Developments11.7 Unijules Life Sciences (India)11.7.1 Unijules Life Sciences (India) Corporation Information11.7.2 Unijules Life Sciences (India) Description and Business Overview11.7.3 Unijules Life Sciences (India) Sales, Revenue and Gross Margin (2015-2020)11.7.4 Unijules Life Sciences (India) Oral Contrast Agent Products Offered11.7.5 Unijules Life Sciences (India) Related Developments11.8 J.B. Chemicals and Pharmaceuticals (India)11.8.1 J.B. Chemicals and Pharmaceuticals (India) Corporation Information11.8.2 J.B. Chemicals and Pharmaceuticals (India) Description and Business Overview11.8.3 J.B. Chemicals and Pharmaceuticals (India) Sales, Revenue and Gross Margin (2015-2020)11.8.4 J.B. Chemicals and Pharmaceuticals (India) Oral Contrast Agent Products Offered11.8.5 J.B. Chemicals and Pharmaceuticals (India) Related Developments11.9 Spago Nanomedicine (Sweden)11.9.1 Spago Nanomedicine (Sweden) Corporation Information11.9.2 Spago Nanomedicine (Sweden) Description and Business Overview11.9.3 Spago Nanomedicine (Sweden) Sales, Revenue and Gross Margin (2015-2020)11.9.4 Spago Nanomedicine (Sweden) Oral Contrast Agent Products Offered11.9.5 Spago Nanomedicine (Sweden) Related Developments11.10 Taejoon Pharm (South Korea)11.10.1 Taejoon Pharm (South Korea) Corporation Information11.10.2 Taejoon Pharm (South Korea) Description and Business Overview11.10.3 Taejoon Pharm (South Korea) Sales, Revenue and Gross Margin (2015-2020)11.10.4 Taejoon Pharm (South Korea) Oral Contrast Agent Products Offered11.10.5 Taejoon Pharm (South Korea) Related Developments11.1 GE Healthcare (US)11.1.1 GE Healthcare (US) Corporation Information11.1.2 GE Healthcare (US) Description and Business Overview11.1.3 GE Healthcare (US) Sales, Revenue and Gross Margin (2015-2020)11.1.4 GE Healthcare (US) Oral Contrast Agent Products Offered11.1.5 GE Healthcare (US) Related Developments11.12 Magnus Health (India)11.12.1 Magnus Health (India) Corporation Information11.12.2 Magnus Health (India) Description and Business Overview11.12.3 Magnus Health (India) Sales, Revenue and Gross Margin (2015-2020)11.12.4 Magnus Health (India) Products Offered11.12.5 Magnus Health (India) Related Developments 12 Future Forecast by Regions (Countries) (2021-2026)12.1 Oral Contrast Agent Market Estimates and Projections by Region12.1.1 Global Oral Contrast Agent Sales Forecast by Regions 2021-202612.1.2 Global Oral Contrast Agent Revenue Forecast by Regions 2021-202612.2 North America Oral Contrast Agent Market Size Forecast (2021-2026)12.2.1 North America: Oral Contrast Agent Sales Forecast (2021-2026)12.2.2 North America: Oral Contrast Agent Revenue Forecast (2021-2026)12.2.3 North America: Oral Contrast Agent Market Size Forecast by Country (2021-2026)12.3 Europe Oral Contrast Agent Market Size Forecast (2021-2026)12.3.1 Europe: Oral Contrast Agent Sales Forecast (2021-2026)12.3.2 Europe: Oral Contrast Agent Revenue Forecast (2021-2026)12.3.3 Europe: Oral Contrast Agent Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Oral Contrast Agent Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Oral Contrast Agent Sales Forecast (2021-2026)12.4.2 Asia Pacific: Oral Contrast Agent Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Oral Contrast Agent Market Size Forecast by Region (2021-2026)12.5 Latin America Oral Contrast Agent Market Size Forecast (2021-2026)12.5.1 Latin America: Oral Contrast Agent Sales Forecast (2021-2026)12.5.2 Latin America: Oral Contrast Agent Revenue Forecast (2021-2026)12.5.3 Latin America: Oral Contrast Agent Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Oral Contrast Agent Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Oral Contrast Agent Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Oral Contrast Agent Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Oral Contrast Agent Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Oral Contrast Agent Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Oral Contrast Agent Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details16.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read more here:
Trending: Oral Contrast Agent Trends, Key Driven Factors, Segmentation And Forecast To 2020-2026 - Bulletin Line

The research study Global Nanomedicine Industry provides strategic appraisal of the Nanomedicine market. Our expedition specialists acutely determine the momentous aspects of the Global Nanomedicine report. It also offers a detail valuation with respect to the future technologies relying on the historical data and present circumstance of Nanomedicine market situation. In this Nanomedicine report, we have examined the principals, manufacturers in the market, geographical regions, product type, and Nanomedicine market end-client applications. The global Nanomedicine report comprises of primary and secondary information which is epitomized in the form of pie- charts, tables, Nanomedicine analytical diagrams, and reference figures. The Nanomedicine report is presented in a competent way, that involves basic patois, basic Nanomedicine overview, agreements, and certain facts as per consolation and comprehension.

For Better Understanding, Request A Free Pdf Sample Copy Of Nanomedicine Market Here@ https://marketresearch.biz/report/nanomedicine-market/request-sample

(***Our FREE SAMPLE COPY of the report offers a quick advent to the studies report outlook, TOC, a listing of tables and figures, an outlook to key players of the market and comprising key regions.)

Additionally, in-depth business outline, Nanomedicine market revenue study, strategies, and SWOT analysis of the top players have been provided in the report. Players in the Global Nanomedicine market are directing to vast their operations to leading regions. Further, Nanomedicine market companies are concentrate on innovation and establishing their products at competitive prices. A detail Nanomedicine supply chain study in the report will give Nanomedicine readers a better understanding.

Furthermore, the worldwide Nanomedicine market report describe segment-wise bifurcation in a way to offer the actual landscaping analogous to the market situation. The global Nanomedicine market is classified into product, application, and region with outstanding market players Pfizer Inc., Merck & Co., Ablynx NV, Nanosphere, Celgene Corporation, Abraxis BioScience, Inc., Teva Pharmaceutical Industries Limited, Inc., Abbott Laboratories, Johnson & Johnson Services, GE Healthcare Limited, Inc. and Inc..

Download Now And Browse Complete Information On The COVID 19 Impact Analysis On Nanomedicine Market:https://marketresearch.biz/report/nanomedicine-market/covid-19-impact

***NOTE: As the world is experiencing the impact of Coronavirus, the MarketResearch.Biz has up to date its global Nanomedicine market research report. Our Team of Industry Researchers are Studying Covid19 and its Impact on Nanomedicine Market Growth and wherever necessary we will be considering Covid19 Footmark for Better Analysis of Market and Industries. Congenially get in Touch for More Details Information.

Market Segmentation:

Global nanomedicine market segmentation by product: Therapeutics, Regenerative medicine, In-vitro diagnostics, In-vivo diagnostics, Vaccines. Global nanomedicine market segmentation by application: Clinical Oncology, Infectious diseases, Clinical Cardiology, Orthopedics, Others

Moving ahead, the Nanomedicine market is influencing the North America market that contains (United States, Canada, and Mexico), Nanomedicine market is growing in Europe market (France, Germany, Italy, UK, and Russia), witnessed growth in the Asia Pacific region (Japan, China Korea, South East Asia and India), followed by Nanomedicine market in South America (Argentina, Columbia and Brazil), and the Middle East and Africa (UAE, Saudi Arabia, Nigeria, Egypt and South Africa).

The global Nanomedicine market reports confront the ebb and flow involved in significant market players. Several Nanomedicine movement, processes, basics, and knowledge are provided in the researching study, that ease our readers to understand the market and can differentiate with the other Nanomedicine market contenders, as well guide in taking an correct decision with regards to Nanomedicine future expectation.

Any Query? Feel Free To Inquire Here: https://marketresearch.biz/report/nanomedicine-market/#inquiry

The data is impersonated from different sites, journals, magazines, research papers and yearly reports from Nanomedicine industries and gathered for advanced judgment. Validation of information is done by carrying out face-to-face interviews with fundamental conclusion experts and pioneers of Nanomedicine industry. Later, it is represented in form of graphs, tables and Nanomedicine market pie-diagrams.

The global Nanomedicine market has been well arranging in 15 chapters:

Chapter 1, Serves the complete assessment of the global Nanomedicine market, risk, mergers and collaboration, product classifications.

Chapter 2, Correlate with the key companies their supply-demand ratio relevant to Nanomedicine raw materials, price format, company revenue and sales.

Chapter 3, Nanomedicine market report disclose geological analysis in terms of income and sales forecasted period 2017-2026.

Chapter 4, The Nanomedicine report focuses on top driving organizations in the growing regions alongside their benefit, agreements, and market volume from 2017 to 2026.

Chapter 5,6,7, an In-sight study of the Nanomedicine market, related to top countries that give sales and revenue contribution in the market.

Chapter 8 and 9, the global Nanomedicine market explore this market through different segments, by product type, end-user applications, their market value, and growth rate.

Chapter 10 and 11, describes the Nanomedicine market circumstances over the forecast period for product type, end-client application, and regional study from 2017 to 2026.

Chapter 13,14 and 15, reveals the processed used in collecting the data, Nanomedicine market overview, different techniques used in the process of research findings, assumptions, appendix and various assets.

Get Complete Table Of Content: https://marketresearch.biz/report/nanomedicine-market/#toc

Altogether, the global Nanomedicine report conducts an extensive investigation of the parent market, to know the overall of the global Nanomedicine market. Moreover, key players guiding the global Nanomedicine market over the market dimension, product scope, strategies, distinct Nanomedicine applications respecting to the market, product type along with the global market detailing and Nanomedicine advance prospects.

About Us:

MarketResearch.Biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge.We offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Contact Us:

Mr. Benni Johnson

Prudour Pvt. Ltd.

420 Lexington Avenue,

Suite 300 New York City, NY 10170,

United States

Tel: + 1-347-826-1876

Email ID: inquiry@marketresearch.biz

Website: https://marketresearch.biz/

View original post here:
Nanomedicine Market Revenue Value(USD Mn), New Business Strategies and CAGR Forecast 2029 - News Monitoring

The report aims to provide a 360-degree view of the market in terms of cutting-edge technology, key developments, drivers, restraints and future trends with impact analysis of these trends on the market for short-term, mid-term and long-term during the forecast period. Further, the report also covers key players profiling with detailed SWOT analysis, financial facts and key developments of products/service from the past three years.

Nanomedicine is the medical application of nanotechnology, and it ranges from the medicinal uses of nanomaterials and biological devices to nano electronic biosensors. However, current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials (materials whose structure is on the scale of nanometers, i.e., billionths of a meter). Also, functionalities can be added to nanomaterials by interfacing them with biological molecules or structures. Thus far, the integration of nanomaterials with biology has led to the development of diagnostic devices, contrast agents, analytical tools, physical therapy applications, and drug delivery vehicles.

Download a Sample Report Explore further @ https://www.theinsightpartners.com/sample/TIPRE00011102/

The nano-medical device market is expected to witness significant growth over the forecast period, due to increasing prevalence of chronic diseases, growing R&D activities. Moreover, rising awareness pertaining to minimally invasive surgical procedures and development of technologically advanced medical devices which are compact, precise and efficient are amongst key factors for the growth of nanomedical devices market over the forecast period.

Key Players Influencing the Market:

1. Affymetrix2. Crucell N.V.3. Flamel Technologies S.A.4. Nektar Therapeutics5. Par Pharmaceutical companies Inc.6. PerkinElmer7. St.Jude Medical8. Starkey Hearing Technologies9. Starpharma Holdings limited10. Stryker Corporation

Market Segmentation :

The nano-medical device market is segmented on the basis of product type, and application. Based on product type, the market is segmented as biochip, implant materials, medical textiles, wound dressing, cardiac rhythm management devices and hearing aid. On the basis of application, the market is categorized as therapeutic, diagnostic and research.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the nano-medical device market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The nano-medical device market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting nano-medical device market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the nano-medical device market in these regions.

Request for Buy Report @ https://www.theinsightpartners.com/buy/TIPRE00011102/

Reasons to Buy the Report:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

The Insight partners,

Phone: +1-646-491-9876Email:[emailprotected]

Excerpt from:
Nano-Medical Device Market 2027 : Which region will gain the largest growth? - Cole of Duty

Labeled cells could be tracked either in cell cultures or once injected into a living animal. Credit: 2020 KAUST

Customizable magnetic iron nanowires pinpoint and track the movements of target cells.

Living cells inside the body could be placed under surveillancetheir location and migration noninvasively tracked in real time over many daysusing a new method developed by researchers at KAUST.

The technique uses magnetic core-shell iron nanowires as nontoxic contrast agents, which can be implanted into live cells, lighting up those cells location inside a living organism when scanned by magnetic resonance imaging (MRI). The technique could have applications ranging from studying and treating cancer to tracking live-cell medical treatments, such as stem cell therapies.

Jrgen Kosel and his team recently showed that core-shell iron nanowires could selectively kill cancer cells with a combination attack, delivering an anticancer drug into target cells while also puncturing the cells membrane and unleashing blasts of heat. Now, in collaboration with researchers from the CIC biomaGUNE in San Sebastian, Spain, the team has shown that the same type of iron core, iron-oxide shell nanowires, can be used for noninvasive medical imaging. The nanowires could potentially be used as theranostic agents, able to identify, track and then take out target cells.

Cell labeling and tracking has become an invaluable tool for scientific and clinical applications, says Aldo Martinez-Banderas, a Ph.D. student in Kosels team. One of the key aspects of cell tracking studies is the sensitivity to detect a small number of cells after implantation, so the strong magnetization and biocompatibility of our nanowires are advantageous characteristics for MRI tracking.

The nanowires performed well as MRI contrast agents, even at very low concentrations, and the magnetic response could be tuned by altering the thickness of the nanowire shell, the team showed. The nanowires biocompatibility permitted long-term tracking of the live cells. The nanowires interacted with cells without compromising their survival, functionality or capacity to proliferate, Martinez-Banderas explains. The labeled cells could be tracked either in cell cultures or once injected into a living animal. The strong magnetization of the nanowires enabled the detection of approximately 10 labeled cells within the brain of a mouse for a period of at least 40 days, which allowed us to trace their exact location and fate in the animal, Martinez-Banderas says.

These core-shell nanowires have various additional features, including the ability to control them magnetically to guide them to a particular location, to carry drugs, or be to heated with a laser, Kosel says. Combining all of that with the capability of tracking creates a theranostic platform that can open the door for very promising new approaches in nanomedicine.

Reference: Magnetic coreshell nanowires as MRI contrast agents for cell tracking by Aldo Isaac Martnez-Banderas, Antonio Aires, Sandra Plaza-Garca, Lorena Cols, Julin A. Moreno, Timothy Ravasi, Jasmeen S. Merzaban, Pedro Ramos-Cabrer, Aitziber L. Cortajarena and Jrgen Kosel, 12 March 2020, Journal of Nanobiotechnology.DOI: 10.1186/s12951-020-00597-3

See the rest here:
Iron Nanorobots Go Undercover to Track Living Cells Inside the Body - SciTechDaily

Endo International

Moreover, the Healthcare Nanotechnology (Nanomedicine) report offers a detailed analysis of the competitive landscape in terms of regions and the major service providers are also highlighted along with attributes of the market overview, business strategies, financials, developments pertaining as well as the product portfolio of the Healthcare Nanotechnology (Nanomedicine) market. Likewise, this report comprises significant data about market segmentation on the basis of type, application, and regional landscape. The Healthcare Nanotechnology (Nanomedicine) market report also provides a brief analysis of the market opportunities and challenges faced by the leading service provides. This report is specially designed to know accurate market insights and market status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=210503&utm_source=NYH&utm_medium=888

Table of Content

1 Introduction of Healthcare Nanotechnology (Nanomedicine) Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Healthcare Nanotechnology (Nanomedicine) Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Healthcare Nanotechnology (Nanomedicine) Market, By Deployment Model

5.1 Overview

6 Healthcare Nanotechnology (Nanomedicine) Market, By Solution

6.1 Overview

7 Healthcare Nanotechnology (Nanomedicine) Market, By Vertical

7.1 Overview

8 Healthcare Nanotechnology (Nanomedicine) Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Healthcare Nanotechnology (Nanomedicine) Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=210503&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Healthcare Nanotechnology (Nanomedicine) Market Size, Healthcare Nanotechnology (Nanomedicine) Market Trends, Healthcare Nanotechnology (Nanomedicine) Market Growth, Healthcare Nanotechnology (Nanomedicine) Market Forecast, Healthcare Nanotechnology (Nanomedicine) Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Our Trending Reports

Fin Tech Blockchain Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Flexible Polyurethane Foam Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Continue reading here:
Healthcare Nanotechnology (Nanomedicine) Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty

SALT LAKE CITY, May 26, 2020 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announcedits Australian subsidiary has completed over 50% of participant randomization in the Phase 2 RESCUE-ALS study with its lead nanocatalytic therapy, CNM-Au8, for the treatment of Amyotrophic Lateral Sclerosis (ALS). The RESCUE-ALS study is substantially funded by FightMND.

The randomized, double-blind, multi-center RESCUE-ALS study is an ongoing study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in early symptomatic ALS patients. The study has to date enrolled 26 subjects of 42 planned participants.

"Enrollment in this Phase 2 study is ahead of schedule and clearly emphasizes the unmet medical need in this devasting disease. In preclinical models of ALS, CNM-Au8 has been shown to promote neuroprotection and reduce neurodegeneration. We believe the unique mechanism of CNM-Au8 provides the potential to be an effective disease-modifying therapy for patients with ALS and we look forward to completing enrollment," said Robert Glanzman, MD, FAAN, Chief Medical Officer of Clene.

"We are excited to achieve this enrollment milestone for our Phase 2 RESCUE-ALS trial and believe we are on track to complete full enrollment in the third quarter of this year," said Rob Etherington, President and CEO of Clene.

About RESCUE-ALS

RESCUE-ALS is Phase 2 multi-center randomized, double-blind, parallel group, placebo-controlled study examining the efficacy, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in participants who are newly symptomatic ALS (within 24-months of screening or 12-months from diagnosis) and with a clinically probable or possible or definite ALS diagnosis. Enrolled subjects will be randomized 1:1 to receive either active treatment with CNM-Au8 30 mg or placebo in addition to their current standard of care. Participants will receive their randomized oral treatment daily over 36 consecutive weeks during the Treatment Period. The treatment is taken by mouth once daily first thing every morning. The objective of this study is to assess bioenergetic catalysis with CNM-Au8 to slow disease progression in patients with ALS.

About CNM-Au8

CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted nanocrystalline gold (Au) that acts catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of gold atoms organized into faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteersand both remyelination and neuroprotection effects in multiple preclinical models. Preclinical data presented at scientific congresses demonstrated that treatment with CNM-Au8 in neuronal cultures improved survival of neurons, protected neurite networks, decreased intracellular levels of reactive oxygen species, and improved mitochondrial capacity in response to cellular stress, induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 improved functional behaviors in a rodent models of ALS, multiple sclerosis, and Parkinson's disease versus vehicle (placebo). CNM-Au8 has received regulatory approval to proceed to clinical studies for the treatment of remyelination failure in patients with multiple sclerosis and neuroprotection in patients with amyotrophic lateral sclerosis(ALS) and Parkinson's disease.

About Amyotrophic Lateral Sclerosis (ALS)

ALS is a universally fatal neurodegenerative disorder that results in loss of motor neurons in the cerebral cortex, brain stem, and spinal cord. ALS, also known as Lou Gehrig's disease, leads to the death of the neurons controlling voluntary muscles resulting in weakness, muscle atrophy, and progressive paralysis. ALS affects more than 15,000 patients in the United States and is the most prevalent adult-onset progressive motor neuron disease.

About Clene

Clene Nanomedicine, Inc. is a privately-held, clinical-stage biopharmaceutical company, focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit http://www.clene.com.

About FightMND

FightMND is a not-for-profit registered charity, founded in 2014. It was established to raise the awareness of Motor Neurone Disease (MND) in Australia, to increase funding for research to find an effective treatment and cure and to provide care equipment for MND patients. We have a clear objective to a have a world free from MND.

FightMND is Australia's largest independent MND foundation focused on funding large- scale, collaborative research and clinical trials. The generous donations contributed by everyday Australians, right across the country, has enabled FightMND to raise and commit millions to cure and care initiatives.

Investor Contact

Kaitlyn BroscoThe Ruth Group646-536-7032[emailprotected]

Media Contact

Kirsten ThomasThe Ruth Group508-280-6592[emailprotected]

SOURCE Clene Nanomedicine, Inc.

clene.com

Read the original here:
Clene Nanomedicine Announces Over 50% of Subjects Randomized in RESCUE-ALS Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis (ALS) with...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced receipt of the French 2019 Prix Galien Award for Most Innovative MedTech. The Companys lead product, HENSIFY (NBTXR3) brand name for the treatment of locally advanced Soft Tissue Sarcoma (STS), was recognized after receiving European market approval (CE marking, DM class III, on April 2, 2019) earlier this year. The Prix Galien Award recognizes outstanding biomedical and medical technology product achievements that improve the human condition.

HENSIFY is a first-in-class radioenhancer consisting of an aqueous suspension of crystalline hafnium oxide nanoparticles. The product is administered only once, directly into the tumor, before a patients first radiotherapy session. After intratumoral injection, the nanoparticles penetrate the tumor cells and, when activated by ionizing radiation, deliver a larger energy deposit within the tumor where the nanoparticles are present, thereby increasing the tumor-killing effect of treatment without increasing damage to surrounding healthy tissues. HENSIFY has a universal, physical mode of action and is inert within the human body outside of the presence of ionizing radiation.

The product is approved in Europe for the treatment of Soft Tissue Sarcoma (STS). Positive results from the Companys phase III STS study were featured the August 2019 edition of The Lancet Oncology.

Moving forward, the Company is engaged in global clinical development of the product across fifteen (15) clinical trials in STS and other indications with a primary focus on global registration for the treatment of Head and Neck cancers. These trials include the expansion phase of a European phase I evaluating the safety and feasibility of NBTXR3 activated by radiation therapy(Study NBTXR3-102); an immuno-oncology (I/O) basket trial (Study NBTXR3-1100) which evaluates NBTXR3 in combination with anti-PD-1 in the United States (US); phase I trials evaluating NBTXR3 activated by radiation therapy for the treatment of liver and prostate cancer; a partnership with PharmaEngine in Asia evaluating NBTXR3 in combination with cisplatin; and a clinical collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) including nine (9) trials across several indications.

About the PRIX GALIEN

Created in France in 1970, the Prix Galien is the most prestigious award in the field of pharmaceutical research and innovation. Referred to as the Nobel Prize of pharmaceutical research, it recognizes the efforts and achievements of pharmaceutical research and development.

About NBTXR3

NBTXR3 is a first-in-class product designed to destroy tumors through physical cell death when activated by radiotherapy. NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide standards of radiation care. The physical mode of action of NBTXR3 makes it applicable across solid tumors such as lung, prostate, liver, glioblastoma, and breast cancers.

NBTXR3 is actively being evaluated in head and neck cancer with locally advanced squamous cell carcinoma of the oral cavity or oropharynx in elderly and frail patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I/II trial regarding local control. In the United States, the company has started the regulatory process in regard to the clinical authorization to the phase II/III in locally advanced head and neck cancers.

Nanobiotix is also running an Immuno-Oncology development program. The Company received approval FDA to launch a clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 antibodies in locoregional recurrent (LRR) or recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) and lung or liver metastasis (mets) with HNSCC not amenable to re-irradiation or non-small cell lung cancer (NSCLC) as the primary tumor.

The other ongoing NBTXR3 trials are treating patients with liver cancers (hepatocellular carcinoma and liver metastasis), locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma. Furthermore, the company has a large-scale, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center (9 new phase I/II clinical trials in the United States) to evaluate NBTXR3 across head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers.

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

See original here:
NANOBIOTIX Receives the 2019 Prix Galien Award for First-in-Class HENSIFY - Business Wire

The European Summit for Clinical Nanomedicine and Targeted Medicine - The Translation to Knowledge Based Nanomedicine

Eighth Conference And Exhibition, June 28 - July 1, 2015

Sunday, June 28, 2015 General Assembly of the European Society for Nanomedicine (15.30 h) Meeting of the International Society for Nanomedicine (16.30 h) Editorial Board Meeting, European Journal of Nanomedicine (18.00 h) Welcome Dinner for Speakers & invited Guests [19.45 Swisstel Le Plaza, 1st Floor]

Co-founded by the Swiss Confederation. Swiss Derpartment of Economic Affairs, Education and Research

Scientific Committee: Prof. Dr. med. Patrick Hunziker, University Hospital Basel (CH) (Chairman) Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL) Dr. med. h.c. Beat Lffler, MA, European Foundation for Clinical Nanomedicine (CLINAM), Basel (CH) Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, (NL) Prof. Dr. Marisa Papaluca Amati, European Medicines Agency, London (GB) Prof. Dr. med. Janos Szebeni, Bay Zoltan Ltd and Semmelweis/Miskolc Universities, Budapest (HU) Prof. Dr. med. Christoph Alexiou, Head and Neck Surgery, University Hospital Erlangen (D) Prof. Dr. Claus-Michael Lehr, Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Saarbrucken (D) Prof. Dr. Gerd Binnig, Founder of Definiens AG, Nobel Laureate, Munich (DE) Patrick Boisseau, CEA-Lti, Chairman of the ETPN, Grenoble (FR) Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zrich (CH) Prof. Dr. Jan Mollenhauer, Director Lundbeckfonden Center of Excellence University of Southern Denmark, Odense (DK) Dr. Yanay Ofran, Systems Biology & Functional Genomics, Bar Ilan University, Ramat Gan (IL)

Conference Venue: Congress Center, Messeplatz 21, 4058 Basel, Switzerland, Phone + 41 58 206 28 28 This email address is being protected from spambots. You need JavaScript enabled to view it.

See original here:
CLINAM - Introduction

Global Nanomedicine Market research report from Crystal Market Research covers overview defines characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market share, trends and strategies for the Nanomedicine industry.The size section gives the revenues, covering both the historic data of the Nanomedicine market and forecasting the future. Drivers and restraints are studied with respect to external factors influencing the growth of the market.

The authors of the Nanomedicine report shed light on lucrative business prospects, prominent trends, regulatory situations, and price scenarios of the global Nanomedicine market. Importantly, the report gives a detailed analysis of macroeconomic and microeconomics factors impacting the growth of the global Nanomedicine market. It is divided into various sections and chapters to help with easy understanding of each and every aspect of the global Nanomedicine market.

Click Here To Access The Sample Report @https://www.crystalmarketresearch.com/report-sample/HC122205

Continue

Check Exclusive Discount on this report @https://www.crystalmarketresearch.com/check-discount/HC122205

To get this report at a profitable rate @ https://www.crystalmarketresearch.com/send-an-enquiry/HC122205

Contacts Us:

Sherry | APAC Marketing Division: Level 23-1, Premier Suite

Mont Kiara, 50480 Kuala Lumpur

Malaysia

E-mail: sales@crystalmarketresearch.com

See the article here:
Innovative Report on Nanomedicine Market with Focusing on Eminent Players- Nanosphere Inc.,Pfizer Inc.,Combimatrix Corp - Finance Daily Tribune

On November 25, 2019, the European Union (EU) Observatory for Nanomaterials (EUON) announced the publication of a study published in Frontiers in Pharmacology entitled Unpredictable Nanoparticle Retention in Commonly Used Plastic Syringes Introduces Dosage Uncertainties That May Compromise the Accuracy of Nanomedicine and Nanotoxicology Studies. The researchers in the study radiolabeled a variety of different nanoparticles, loaded suspensions of particles into different plastic syringes, and then measured the radioactivity left behind after emptying the nanoparticle suspension from the syringe. This provided a simple way to measure the fraction of nanoparticles that remained stuck inside the syringe. According to EUON, in the worst case, up to 79.1 percent of the nanoparticles remained. The study found variability in the amounts remaining behind depending on the types of particles and syringes used. The researchers propose checks to determine the correct combination of syringe and nanoparticle that should be used to minimize the problem. The study did not identify the root causes of the high variability between the different nanoparticles and syringe types used.

Go here to see the original:
Researchers Find Nanotoxicity Studies May Be Affected by Nanoparticles Staying Behind in Syringes - Lexology

Chicago, United States: The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the globalNanorobotics MarketMarket. It includes Porters Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Nanorobotics Market Market. We have provided deep analysis of the vendor landscape to give you a complete picture of current and future competitive scenarios of the global Nanorobotics Market market. Our analysts use the latest primary and secondary research techniques and tools to prepare comprehensive and accurate market research reports.

Top Key players cited in the report: Bruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments, EV Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik

The final report will add the analysis of the Impact of Covid-19 in this report Nanorobotics MarketMarket

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart)

Segmentation by Application: Nanomedicine, Biomedical, Mechanical

Segmentation by Type:Nanomanipulator, Bio-Nanorobotics, Magnetically Guided, Bacteria-Based

Each segment of the global Nanorobotics Market market is extensively evaluated in the research study. The segmental analysis offered in the report pinpoints key opportunities available in the global Nanorobotics Market market through leading segments. The regional study of the global Nanorobotics Market market included in the report helps readers to gain a sound understanding of the development of different geographical markets in recent years and also going forth. We have provided a detailed study on the critical dynamics of the global Nanorobotics Market market, which include the market influence and market effect factors, drivers, challenges, restraints, trends, and prospects. The research study also includes other types of analysis such as qualitative and quantitative.

Global Nanorobotics Market Market: Competitive Rivalry

The chapter on company profiles studies the various companies operating in the global Nanorobotics Market market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Nanorobotics Market market participants in the past few years to remain ahead of the competition.

Global Nanorobotics Market Market: Regional Segments

The chapter on regional segmentation details the regional aspects of the global Nanorobotics Market market. This chapter explains the regulatory framework that is likely to impact the overall market. It highlights the political scenario in the market and the anticipates its influence on the global Nanorobotics Market market.

The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Request For Customization:https://www.reporthive.com/request_customization/2296484

Report Highlights

Comprehensive pricing analysis on the basis of product, application, and regional segments

The detailed assessment of the vendor landscape and leading companies to help understand the level of competition in the global Nanorobotics Market market

Deep insights about regulatory and investment scenarios of the global Nanorobotics Market market

Analysis of market effect factors and their impact on the forecast and outlook of the global Nanorobotics Market market

A roadmap of growth opportunities available in the global Nanorobotics Market market with the identification of key factors

The exhaustive analysis of various trends of the global Nanorobotics Market market to help identify market developments

Table of Contents

Report Overview:It includes six chapters, viz. research scope, major manufacturers covered, market segments by type, Nanorobotics Market market segments by application, study objectives, and years considered.

Global Growth Trends:There are three chapters included in this section, i.e. industry trends, the growth rate of key producers, and production analysis.

Nanorobotics Market Market Share by Manufacturer:Here, production, revenue, and price analysis by the manufacturer are included along with other chapters such as expansion plans and merger and acquisition, products offered by key manufacturers, and areas served and headquarters distribution.

Market Size by Type:It includes analysis of price, production value market share, and production market share by type.

Market Size by Application:This section includes Nanorobotics Market market consumption analysis by application.

Profiles of Manufacturers:Here, leading players of the global Nanorobotics Market market are studied based on sales area, key products, gross margin, revenue, price, and production.

Nanorobotics Market Market Value Chain and Sales Channel Analysis:It includes customer, distributor, Nanorobotics Market market value chain, and sales channel analysis.

Market Forecast Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

Get Free Sample Copy of this report: https://www.reporthive.com/request_sample/2296484

About Us:Report Hive Research delivers strategic market research reports, statistical survey, and Industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of United States Business Leaders, Government Organizations, SMEs, Individual and Start-ups, Management Consulting Firms, and Universities etc. Our library of 600,000+ market reports covers industries like Chemical, Healthcare, IT, Telecom, Semiconductor, etc. in the USA, Europe Middle East, Africa, Asia Pacific. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio and application analysis etc.

Link:
COVID-19 impact on Nanorobotics Market Research, Development, Top Companies, Trends and Growth 2020 to 2025: Bruker, JEOL, Thermo Fisher Scientific -...

New Jersey, United States,- A detailed research study on Healthcare Nanotechnology (Nanomedicine) Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Healthcare Nanotechnology (Nanomedicine), to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=210503&utm_source=COD&utm_medium=888

Leading Healthcare Nanotechnology (Nanomedicine) manufacturers/companies operating at both regional and global levels:

Healthcare Nanotechnology (Nanomedicine) Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Healthcare Nanotechnology (Nanomedicine) market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Healthcare Nanotechnology (Nanomedicine) market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Healthcare Nanotechnology (Nanomedicine) Market, By Product

Healthcare Nanotechnology (Nanomedicine) Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=210503&utm_source=COD&utm_medium=888

Healthcare Nanotechnology (Nanomedicine) Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Healthcare Nanotechnology (Nanomedicine) market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Healthcare Nanotechnology (Nanomedicine) Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Healthcare Nanotechnology (Nanomedicine) Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Healthcare Nanotechnology (Nanomedicine) Market, By Deployment Model

5.1 Overview

6 Healthcare Nanotechnology (Nanomedicine) Market, By Solution

6.1 Overview

7 Healthcare Nanotechnology (Nanomedicine) Market, By Vertical

7.1 Overview

8 Healthcare Nanotechnology (Nanomedicine) Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Healthcare Nanotechnology (Nanomedicine) Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=210503&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Printed Cartons Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Printed Sensor Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Printing for Packaging Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the original post:
Healthcare Nanotechnology (Nanomedicine) Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of...

Endo International

Global Healthcare Nanotechnology (Nanomedicine) Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=210503&utm_source=LHN&utm_medium=888

Healthcare Nanotechnology (Nanomedicine) Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Healthcare Nanotechnology (Nanomedicine) industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Healthcare Nanotechnology (Nanomedicine) industry.

-> Furthermore, we will help you to identify any crucial trends to predict Healthcare Nanotechnology (Nanomedicine) market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Healthcare Nanotechnology (Nanomedicine) market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=210503&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Healthcare Nanotechnology (Nanomedicine) market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Healthcare Nanotechnology (Nanomedicine) market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Healthcare Nanotechnology (Nanomedicine) Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Healthcare Nanotechnology (Nanomedicine) Market Size, Healthcare Nanotechnology (Nanomedicine) Market Growth, Healthcare Nanotechnology (Nanomedicine) Market Forecast, Healthcare Nanotechnology (Nanomedicine) Market Analysis

Our Trending Reports

Probiotics in Animal Feed Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Product Compliance Software Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Continue reading here:
Healthcare Nanotechnology (Nanomedicine) Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

MagForce AG / Key word(s): StudyMagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Protocol for the next Stage of Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System

27-Apr-2020 / 23:51 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

MagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Protocol for the next Stage of Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System

Berlin, Germany, and Nevada, USA, April 27, 2020 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc., today announced that FDA approval for a streamlined trial protocol, for the next stage of the Company's pivotal U.S. study with the NanoTherm therapy system for the focal ablation of intermediate risk prostate cancer was received. The next stage of the clinical trial is being initiated with three well-respected urological centers in Texas, Washington and Florida who actively enrolled patients in Stage 1.

The streamlined procedure will allow the patient treatment to be completed within one day at one of MagForce's three out-patient treatment facilities and is possible because of limited side effects that were observed at each step of the procedure in Stage 1.

The next stage of the study will be conducted in phases to ensure early on that the minimal side effects observed in Stage 1, with a drawn out procedure, are maintained in the streamlined one day procedure. Treatment of the first 5 to10 subjects should be sufficient to affirm the minimal side effects as expected.

COVID-19 impact: While there are many restrictions that have been applied such as "Shelter at Home" and eliminating state to state travel via car or via plane; however, MagForce is still working diligently with its physician investigators. Exemptions exist for healthcare workers, such as MagForce's USA staff at MagForce USA clinical facilities. Clearly MagForce USA can conduct the trial in its out-patient facilities and has developed COVID-19 infection control procedures for staff and study subjects. All this effort has caused a certain delay but MagForce is confident the next stage of the clinical trial will not be unduly delayed since MagForce USA will conduct the trial from its facilities.

MagForce is still hopeful that the COVID-19 pandemic will not cause significant delay beyond 2020 to complete this single-arm clinical trial.

- End of Insider Information -

Contact:MagForce AG, Max-Planck-Strae 3, 12489 BerlinBarbara von FrankenbergVice President Communications & Investor RelationsT +49-30-308380-77E-Mail: bfrankenberg@magforce.com

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

27-Apr-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Read the original:
MagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Prot - PharmiWeb.com

In 2018, the market size of Contrast Agents for Magnetic Resonance Imaging (MRI) Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

The report on the Contrast Agents for Magnetic Resonance Imaging (MRI) market provides a birds eye view of the current proceeding within the Contrast Agents for Magnetic Resonance Imaging (MRI) market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Contrast Agents for Magnetic Resonance Imaging (MRI) market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Contrast Agents for Magnetic Resonance Imaging (MRI) market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2554066&source=atm

This study presents the Contrast Agents for Magnetic Resonance Imaging (MRI) Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Contrast Agents for Magnetic Resonance Imaging (MRI) history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

In global Contrast Agents for Magnetic Resonance Imaging (MRI) market, the following companies are covered:

The following manufacturers are covered:GE Healthcare (US)Bracco Imaging (Italy)Bayer HealthCare (Germany)Guerbet (France)Lantheus (US)Daiichi Sankyo (Japan)Unijules Life Sciences (India)J.B. Chemicals and Pharmaceuticals (India)Spago Nanomedicine (Sweden)Taejoon Pharm (South Korea)Jodas (India)Magnus Health (India)

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeBarium-based Contrast MediaIodinated Contrast MediaGadolinium-based Contrast MediaMicrobubble Contrast Media

Segment by ApplicationRadiologyInterventional RadiologyInterventional Cardiology

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2554066&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Contrast Agents for Magnetic Resonance Imaging (MRI) product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Contrast Agents for Magnetic Resonance Imaging (MRI) , with price, sales, revenue and global market share of Contrast Agents for Magnetic Resonance Imaging (MRI) in 2017 and 2018.

Chapter 3, the Contrast Agents for Magnetic Resonance Imaging (MRI) competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Contrast Agents for Magnetic Resonance Imaging (MRI) breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2554066&licType=S&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, Contrast Agents for Magnetic Resonance Imaging (MRI) market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe Contrast Agents for Magnetic Resonance Imaging (MRI) sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Original post:
Impact of COVID-19 Outbreak on Contrast Agents for Magnetic Resonance Imaging (MRI) Market Analysis 2019 Growth by Top Companies and Trends by Types,...